The content summarizes two significant studies presented at ECTRIMS 2024 related to neuromyelitis optica spectrum disorder (NMOSD):
A study from China identified four peripheral inflammatory biomarkers that could predict disease relapse within a year. This is a notable finding, as early detection of potential relapses can help clinicians better manage the condition.
A Harvard study examined treatment outcomes in 107 patients with NMOSD, primarily aquaporin-4–positive women. The study compared traditional therapies like rituximab and azathioprine with newer treatments such as satralizumab and eculizumab. The findings indicate that the older drugs had high failure rates, whereas the newer medications demonstrated much lower relapse rates and hospitalizations. This suggests that the newer treatments should be prioritized due to their higher efficacy and safety profiles.
Overall, these studies provide valuable insights into the potential use of peripheral biomarkers for predicting NMOSD disease course, as well as the comparative effectiveness of different treatment options for this complex neurological condition.
Til et andet sprog
fra kildeindhold
www.medscape.com
Vigtigste indsigter udtrukket fra
by Joseph R. Be... kl. www.medscape.com 09-26-2024
https://www.medscape.com/viewarticle/1001447Dybere Forespørgsler